We are live on
!
Find out more
HCM
Harvey Capital Management Portfolio holdings
AUM
$439M
1-Year Est. Return
37.68%
This Fund
S&P 500
This Quarter
Est. Return
+12.01%
1 Year Est. Return
+37.68%
3 Year Est. Return
+140.63%
5 Year Est. Return
+188.51%
10 Year Est. Return
+681.53%
AUM
$161M
AUM Growth
–
Cap. Flow
+$158M
Cap. Flow
% of AUM
98.25%
Top 10 Holdings %
Top 10 Hldgs %
48.72%
Holding
58
New
58
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$9.8M |
| 2 |
Apple
AAPL
|
+$9.67M |
| 3 |
Gilead Sciences
GILD
|
+$8.72M |
| 4 |
Qualcomm
QCOM
|
+$8.67M |
| 5 |
NPSP
NPS PHARMACEUTICALS INC
NPSP
|
+$7.33M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.48% |
| 2 | Healthcare | 19.71% |
| 3 | Energy | 14.21% |
| 4 | Communication Services | 7.65% |
| 5 | Consumer Discretionary | 7.56% |
Similar funds
STCG
CDMG
WAS
DCM
DA
CCT
SCP
CAAM
Harvey Capital Management's Q2 2013 Portfolio in Review
Q2 2013 is the first quarter with a 13F filing on record for Harvey Capital Management, which disclosed 58 positions worth $161M. Its ten largest holdings account for 49% of the portfolio.
Its largest position is Celgene Corp: 162,800 shares worth $9.52M.
By sector, the portfolio is most concentrated in Technology at 25% of assets, followed by Healthcare and Energy.
- Harvey Capital Management's largest Q2 2013 buy was Celgene Corp: 162,800 shares worth $9.52M.
- Harvey Capital Management's ten largest holdings make up 49% of its $161M portfolio in Q2 2013.
- Harvey Capital Management disclosed 58 positions in Q2 2013, its first 13F filing on record.
Based on Harvey Capital Management's 13F filing for Q2 2013, filed 16 Jul 2013.